Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MC4R | P32245 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | MC3R | P41968 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687671 | 1.00 | ADORA3 (0.62) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL27759666 | 0.98 | ADORA3 (0.60) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL9319560 | 0.82 | ADORA3 (0.55) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL16011499 | 0.78 | KDM4E (0.59) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL29408106 | 0.77 | — | — | |
| Pyrazinamide SCHEMBL24102 | 0.77 | — | — | |
| Pyrazinamide SCHEMBL18364989 | 0.77 | — | — | |
| Pyrazinamide SCHEMBL18364991 | 0.77 | — | — | |
| Pyrazinamide SCHEMBL29518620 | 0.77 | — | — | |
| Pyrazinamide SCHEMBL2433265 | 0.77 | ADORA3 (1.00) | ADORA3TSHRMC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| EP-3624773-A1 | OPHTHALMIC COMPOSITIONS AND METHODS OF USE | Ocugen, Inc. (US) | 2020-03-25 | — | — | EP | claimed |
| US-20180333414-A1 | OPHTHALMIC COMPOSITIONS AND METHODS OF USE | Ocugen, Inc. (US) | 2018-11-22 | — | — | US | claimed |
| WO-2018212846-A1 | OPHTHALMIC COMPOSITIONS AND METHODS OF USE | Ocugen, Inc. (US) | 2018-11-22 | — | — | WO | claimed |
| US-7956059-B2 | Aliphatic amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2011-06-07 | — | — | US | claimed |
| JP-4679505-B2 | — | — | 2011-04-27 | — | — | JP | claimed |
| US-7842697-B2 | Soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-11-30 | — | — | US | claimed |
| US-20090324724-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-12-31 | — | — | US | claimed |
| US-20090227594-A1 | ALIPHATIC AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. | 2009-09-10 | — | — | US | claimed |
| US-4920123-A | ADMINISTERING SUBSTITUTED PYRAZINES | BEYER JR KARL H (US) | 1990-04-24 | — | — | US | claimed |
| US-4894376-A | Methods of treating diseases characterized by hyperexcitability of neurons | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1990-01-16 | — | — | US | claimed |
| US-4663322-A | Antihypertensive hyperuretic and saluretic agent combinations | BEYER JR KARL H (US) | 1987-05-05 | — | — | US | claimed |
| US-4604394-A | Antiarrhythmic compositions and method | MERCK & CO., INC. (US) | 1986-08-05 | — | — | US | claimed |
| US-4594349-A | Containing a pyrimidine ring | BEYER JR KARL H (US) | 1986-06-10 | — | — | US | claimed |
| EP-0083779-A1 | Hyperuretic agents | Beyer, Karl H., Jr. (US) | 1983-07-20 | — | — | EP | claimed |
| EP-0017153-B1 | NOVEL PYRAZINECARBOXAMIDES, PROCESSES FOR PREPARING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | MERCK & CO. INC. (US) | 1983-01-26 | — | — | EP | claimed |
| EP-0017153-A1 | Novel pyrazinecarboxamides, processes for preparing and pharmaceutical compositions containing the same | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | claimed |
| US-4224447-A | DIURETICS | MERCK & CO., INC. (US) | 1980-09-23 | — | — | US | claimed |
| EP-0009054-A1 | N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same | MERCK & CO. INC. (US) | 1980-04-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227594-A1 | ALIPHATIC AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | KCNH2, CACNA1B, SCNN1G | ADORA3 1073/4885TSHR 2666/4885MC4R 2129/4885 |
| US-20090324724-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | ADORA3 844/4885TSHR 2287/4885MC4R 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.